Board of Directors
Dr. Bernd Liesenfeld
Dr. Liesenfeld joined Quick-Med in 2004 and led the development of the NIMBUS® technology used in the Bioguard line of products licensed to Derma Sciences. He has been involved in all aspects of commercializing Quick-Med's antimicrobial technologies, including biochemistry, biosafety, regulatory and production development. Dr. Liesenfeld also led the Quick-Med team that received the top industrial research prize at the 2011 Wound Healing Society meeting for U.S. Army-sponsored research that showed improved wound healing in an animal model of vesicant injury using an advanced multi-feature NIMBUS dressing. Dr. Liesenfeld received a Ph.D. in Materials Science and Engineering from the University of Florida and holds a Bachelor's degree in Mechanical Engineering and Management from the University of Vermont.
Gerald M. Olderman, Ph.D.
Dr. Olderman served as Vice President of Research and Development at Quick-Med Technologies from 1997 to 2012. He has over 35 years of health care industry experience, including 31 years managing product development teams and 25 years heading research and development for major product divisions at three Fortune 500 companies. Previously, Dr. Olderman was vice president of research & development for Surgikos, Inc., a Johnson & Johnson Company; and vice president of international & domestic development for Pharmaseal, a division of Baxter Healthcare Corporation. Dr. Olderman received a B.S. in Chemistry from Rensselaer Polytechnic Institute; and holds an M.S. in Physical Chemistry and a Ph.D. in Physical Chemistry from Seton Hall University.
Gregory S. Schultz, Ph.D.
Dr. Schultz has served as a Board member and Scientific Advisor since July 2000. From 1999 through 2001, Dr. Schultz served as President of the Wound Healing Society, and has consulted 12 major biotechnology companies. In 1989, he was appointed Professor of Obstetrics/Gynecology and Director of the Institute for Wound Research at the College of Medicine at the University of Florida at Gainesville, Florida. He has published over 200 research articles and book chapters that have been cited over 4,000 times. Dr. Schultz’s work on the treatment of burns with growth factors has been funded by major grants from the National Institutes of Health (NIH) and the U.S. Army. Dr. Schultz earned a doctorate in biochemistry from Oklahoma State University and postdoctoral fellowship in cell biology at Yale University.
Mr. Bergman has practiced corporate and securities law for over 25 years, with specialty in advising emerging and mid-market public companies in their growth. Since March 2011, he has been a partner in the Ft. Lauderdale office of Roetzel & Andress, LPA. From May 2009 to March 2011, he was a partner in the Ft. Lauderdale office of Arnstein & Lehr and from January 2004 to April 2009, he was a member of Kluger, Peretz, Kaplan & Berlin, P.L., a Miami-Florida based law firm. Mr. Bergman does not currently serve as a director of any reporting companies. Mr. Bergman, who is a member of the Florida and New York bars, holds a bachelor’s degree from Columbia College of Columbia University and a J.D. from Harvard Law School.
Mr. Jenssen has over 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). From 2006 until the present, Mr. Jenssen was the President of Jenssen Consulting, a business involved in providing strategic planning, process improvement, finance and accounting related services. Mr. Jenssen does not serve as a director of any other reporting company. Mr. Jenssen is a CPA, has an MBA from Columbia University in New York and has held several securities licenses.